Boston Scientific's Watchman stroke prevention device approved after 4 years

Boston Scientific's Watchman device, an alternative to blood thinners for stroke prevention, has earned approval in the U.S. four years after the medical device giant bought the product in its $375 million acquisition of Atritech. The Watchman Left Atrial Appendage Closure Device has been called one of "the two most meaningful pipeline products (along with the Synergy stent) expected to launch over the next few years" by Leerink Partners analyst Danielle Antalffy. Mike Mahoney, the CEO of Marlborough,…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Source Type: news